ScholarIQanswers from OpenAlex & ORCID
Patrick Y. Wen
ResearcherPublications, citations & collaboration network
Patrick Y. Wen is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Patrick Y. Wen have?
ScholarIQindexed works
Patrick Y. Wen has 1,915 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Patrick Y. Wen have?
ScholarIQcitation count
Patrick Y. Wen has 90,083 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Patrick Y. Wen?
ScholarIQh-index
Patrick Y. Wen has an h-index of 148 in OpenAlex.
What is the i10-index of Patrick Y. Wen?
ScholarIQi10-index
Patrick Y. Wen has an i10-index of 678 in OpenAlex.
What is the ORCID of Patrick Y. Wen?
ScholarIQorcid
The ORCID for Patrick Y. Wen is on the source record.
What is the OpenAlex record for Patrick Y. Wen?
ScholarIQopenalex
The OpenAlex for Patrick Y. Wen is on the source record.
What are the most-cited papers on Patrick Y. Wen?
ScholarIQmost cited works
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla, Willy Hugo, Alex Lee, Tom B. Davidson, Anthony Wang, Benjamin M. Ellingson, Julie Rytlewski, Catherine Sanders, Eric S. Kawaguchi, Lin Du, Gang Li, William H. Yong, Sarah Gaffey, Adam L. Cohen, Ingo K. Mellinghoff, Eudocia Q. Lee, David A. Reardon, Barbara O’Brien, Nicholas Butowski, Phioanh L. Nghiemphu, Jennifer Clarke, Isabel Arrillaga‐Romany, Howard Colman, Thomas Kaley, John de Groot, Linda M. Liau, Patrick Y. Wen, Robert M. Prins
Bevacizumab for recurrent malignant gliomas
Andrew D. Norden, Geoffrey S. Young, Kian Setayesh, Alona Muzikansky, Roman A. Klufas, Gary Ross, A. S. Ciampa, L. G. Ebbeling, Brenda Levy, Jan Drappatz, Santosh Kesari, Patrick Y. Wen
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada, Michael Weller, Raymond Y. Huang, Gaetano Finocchiaro, Mark R. Gilbert, Wolfgang Wick, Benjamin M. Ellingson, Naoya Hashimoto, Ian F. Pollack, Alba A. Brandes, Enrico Franceschi, Christel Herold‐Mende, Lakshmi Nayak, Ashok Panigrahy, Whitney B. Pope, Robert M. Prins, John H. Sampson, Patrick Y. Wen, David A. Reardon
Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, John Hilton, Aejaz Nasir, Richard P. Beckmann, Andrew E. Schade, Angie D. Fulford, Tuan S. Nguyen, Ricardo Martínez, Palaniappan Kulanthaivel, Lily Q. Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma
Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, Mehdi Touat, Katherine B. Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust‐Katz, Liam Welsh, Warren Mason, François Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F. Hottinger, Yoshiki Arakawa, Juan Manuel Sepúlveda-Sánchez, Wolfgang Wick, Riccardo Soffietti, James Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth A. Maher, Steven Schoenfeld, Dan Zhao, Shuchi S. Pandya, Lori Steelman, Islam Hassan, Patrick Y. Wen, Timothy F. Cloughesy